Table 2.
Association between standardized serum immunoglobulins and prevalent dementia
| N events/total | Odds Ratio (95% Confidence interval) | |||
|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | ||
| IgA full range | 74/8767 | 1.14 (0.96–1.36) | 1.16 (0.97–1.40) | 1.12 (0.92–1.38) |
| IgA reference rangea | 47/7030 | 1.07 (0.74–1.53) | 1.11 (0.74–1.67) | 1.07 (0.70–1.64) |
| IgG full range | 74/8757 | 1.05 (0.88–1.25) | 1.00 (0.83–1.21) | 0.99 (0.80–1.21) |
| IgG reference rangea | 50/7029 | 0.82 (0.57–1.19) | 0.80 (0.53–1.21) | 0.80 (0.52–1.24) |
| IgM full range | 74/8763 | 0.95 (0.76–1.20) | 1.00 (0.79–1.25) | 1.01 (0.81–1.27) |
| IgM reference rangea | 54/7062 | 1.05 (0.54–2.03) | 1.10 (0.55–2.21) | 1.07 (0.54–2.12) |
Model 1 is adjusted for age and sex; model 2 is adjusted for model 1, smoking status, alcohol consumption, highest education, and APOE ε4 carrier status; model 3 is adjusted for model 2, body mass index, hypertension, total serum cholesterol, diabetes mellitus, history of coronary heart disease, and history of stroke
IgA immunoglobulin A, IgG immunoglobulin G, IgM immunoglobulin M
aComprises 0.86–4.76 g/L for IgA, 6.20–15.10 g/L for IgG, and 0.28–2.64 g/L for IgM, and exclusion of users of medication known to influence serum immunoglobulin levels (systemic corticosteroids, antiepileptic drugs, angiotensin converting enzyme inhibitors, cytostatics, immuno-modulating and/or immunosuppressive drugs)